Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$140 Mln
P/E Ratio
--
P/B Ratio
2.16
Industry P/E
--
Debt to Equity
3.94
ROE
-29.56 %
ROCE
-0.34 %
Div. Yield
0 %
Book Value
105.71
EPS
-0.89
CFO
$-88.33 Mln
EBITDA
$-140.33 Mln
Net Profit
$-150.27 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lucid Diagnostics Inc (LUCD)
| 53.29 | -20.57 | 39.57 | 83.72 | -15.90 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Lucid Diagnostics Inc (LUCD)
| -41.68 | 3.68 | -74.67 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.70 | 10,562.04 | 12.43 | 12.69 | |
| 73.09 | 10,050.19 | 97.07 | 2.52 | |
| 296.97 | 11,609.25 | 277.57 | 3.65 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and... cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc. Address: 360 Madison Avenue, New York, NY, United States, 10017 Read more
Chairman & CEO
Dr. Lishan Aklog M.D.
Chairman & CEO
Dr. Lishan Aklog M.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lucid Diagnostics Inc (LUCD) stood at $ 30,715 Mln as on 31-Dec-24
The share price of Lucid Diagnostics Inc (LUCD) is $1.26 (NASDAQ) as of 29-Apr-2025 13:37 EDT. Lucid Diagnostics Inc (LUCD) has given a return of -15.9% in the last 3 years.
Lucid Diagnostics Inc (LUCD) has a market capitalisation of $ 140 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Lucid Diagnostics Inc (LUCD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lucid Diagnostics Inc (LUCD) and enter the required number of quantities and click on buy to purchase the shares of Lucid Diagnostics Inc (LUCD).
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc. Address: 360 Madison Avenue, New York, NY, United States, 10017
The CEO & director of Dr. Lishan Aklog M.D.. is Lucid Diagnostics Inc (LUCD), and CFO & Sr. VP is Dr. Lishan Aklog M.D..
There is no promoter pledging in Lucid Diagnostics Inc (LUCD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,078
|
|
|
1,054
|
|
|
964
|
| Lucid Diagnostics Inc (LUCD) | Ratios |
|---|---|
|
Return on equity(%)
|
-1.69
|
|
Operating margin(%)
|
-1059.67
|
|
Net Margin(%)
|
-1.05
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lucid Diagnostics Inc (LUCD) was $0 Mln.
$-0.03
(
